Antengene 과거 수익 실적

과거 기준 확인 0/6

Antengene은 연평균 23%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 5.7%의 비율로 수입이 증가했습니다. 매출은 연평균 30.1%의 비율로 증가했습니다.

주요 정보

23.0%

수익 성장률

39.5%

EPS 성장률

Pharmaceuticals 산업 성장	5.6%
매출 성장률	30.1%
자기자본 수익률	-53.3%
순이익	-944.4%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Jan 09

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Sep 20

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

Apr 03

What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Feb 22

수익 및 비용 분석

Antengene 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:6996 수익, 비용 및 수입 (CNY Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	56	-530	283	310
31 Mar 24	62	-555	312	358
31 Dec 23	67	-581	341	406
30 Sep 23	123	-628	429	470
30 Jun 23	178	-676	518	535
31 Mar 23	169	-639	520	512
31 Dec 22	160	-601	522	488
30 Sep 22	121	-584	429	469
30 Jun 22	83	-567	335	449
31 Mar 22	56	-611	286	427
31 Dec 21	29	-656	237	405
30 Sep 21	14	-1,640	201	359
30 Jun 21	-2	-2,624	165	313
31 Mar 21	-1	-2,777	160	330
31 Dec 20	0	-2,929	155	348
30 Sep 20	4	-1,842	124	307
30 Jun 20	8	-755	93	267
31 Mar 20	10	-539	66	191
31 Dec 19	11	-324	39	116
31 Dec 18	7	-146	25	116

양질의 수익: 6996 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 6996 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 6996 은(는) 수익성이 없지만 지난 5년 동안 연간 23% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 6996 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 6996 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 9.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 6996 현재 수익성이 없기 때문에 마이너스 자본 수익률( -53.29% )을 갖습니다.

Antengene 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First half 2024 earnings: EPS and revenues exceed analyst expectations

First half 2024 earnings: EPS and revenues exceed analyst expectations

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Recent updates

South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO

First half 2024 earnings: EPS and revenues exceed analyst expectations

Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications

New minor risk - Share price stability

Consensus revenue estimates decrease by 32%, EPS upgraded

First half 2024 earnings: EPS and revenues exceed analyst expectations

Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024

Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024

Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

New minor risk - Share price stability

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Antengene Corporation Limited Announces Executive Changes

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Less than half of directors are independent

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Less than half of directors are independent

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth